Latest & greatest articles for digoxin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on digoxin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on digoxin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for digoxin

1. Digoxin

Digoxin Top results for digoxin - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for digoxin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Digoxin and Mortality in Patients With Atrial Fibrillation

Digoxin and Mortality in Patients With Atrial Fibrillation 29519345 2018 03 09 1558-3597 71 10 2018 Mar 13 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Digoxin and Mortality in Patients With Atrial Fibrillation. 1063-1074 S0735-1097(18)30103-7 10.1016/j.jacc.2017.12.060 Digoxin is widely used in patients with atrial fibrillation (AF). The goal of this paper was to explore whether digoxin use was independently associated with increased mortality in patients with AF and (...) if the association was modified by heart failure and/or serum digoxin concentration. The association between digoxin use and mortality was assessed in 17,897 patients by using a propensity score-adjusted analysis and in new digoxin users during the trial versus propensity score-matched control participants. The authors investigated the independent association between serum digoxin concentration and mortality after multivariable adjustment. At baseline, 5,824 (32.5%) patients were receiving digoxin. Baseline

EvidenceUpdates2018

4. Digoxin overdose

Digoxin overdose Digoxin overdose - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Digoxin overdose Last reviewed: August 2018 Last updated: March 2018 Summary Can be acute or chronic, intentional, or accidental. Typically presents with components of GI, constitutional, and/or cardiovascular symptoms. Diagnosis is based on symptoms and laboratory data. At therapeutic digoxin doses (0.6-1.2 nanomol/L [0.5 to 0.9 (...) nanograms/mL]), the ECG typically shows PR-interval prolongation and a scooped ST segment. In overdose, ECG also shows signs of increased automaticity (PVCs), AV nodal blockade, and slowed ventricular response. Treatment includes digoxin-specific antibody fragments and supportive care. Lidocaine and phenytoin can be used for cardiac dysrhythmias when antibody fragments are unavailable. There are no long-term complications of poisoning in patients treated appropriately for chronic digoxin toxicity

BMJ Best Practice2018

7. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in BACKGROUND: Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily (...) Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). METHODS: For this retrospective analysis, we included and classified patients from ROCKET AF on the basis of digoxin use at baseline and during the study. Patients in ROCKET AF were recruited from 45 countries and had AF and risk factors putting them at moderate-to-high risk of stroke, with or without heart failure. We used Cox proportional hazards

Lancet2015

8. Cohort study: Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure

Cohort study: Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure Article Text Prognosis Cohort study Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart

Evidence-Based Medicine (Requires free registration)2014

9. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial

Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial 23592708 2013 05 22 2013 08 08 2016 10 19 1522-9645 34 20 2013 May European heart journal Eur. Heart J. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. 1489-97 10.1093/eurheartj/eht120 Digoxin is recommended (...) for long-term rate control in paroxysmal, persistent, and permanent atrial fibrillation (AF). While some analyses suggest an association of digoxin with a higher mortality in AF, the intrinsic nature of this association has not been examined in propensity-matched cohorts, which is the objective of the current study. In Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM), 4060 patients with paroxysmal and persistent AF were randomized to rate (n = 2027) vs. rhythm (n = 2033

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

10. Influence of gastric acidity on the bioavailability of digoxin.

Influence of gastric acidity on the bioavailability of digoxin. Influence of gastric acidity on t... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1991 ) Volume: 115 , Issue: 7 , Pages: 540-545 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To study how changes in gastric acidity induced by omeprazole and pentagastrin affect the absorption of unchanged digoxin and its (...) hydrolytic breakdown products. DESIGN: Double-blind, double-dummy, randomized, crossover study. SETTING: Academic department of clinical pharmacology. SUBJECTS: Six healthy male volunteers. INTERVENTIONS: Subjects received digoxin, 1 mg orally, on three separate occasions: first, after pretreatment with omeprazole; second, after pretreatment with pentagastrin; and third, after "pretreatment" with placebo. MEASUREMENTS: The in-vitro decomposition of digoxin wa studied using a standard dissolution test

Annals of Internal Medicine2013

11. Digoxin use and the risk of breast cancer in women

Digoxin use and the risk of breast cancer in women 21422417 2011 05 30 2011 07 28 2013 11 21 1527-7755 29 16 2011 Jun 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Digoxin use and the risk of breast cancer in women. 2165-70 10.1200/JCO.2010.32.8146 Digoxin resembles estrogen chemically and may have estrogenic effect. We hypothesized that digoxin use might increase breast cancer incidence and examined if use might be associated (...) with risk of breast cancer, categorized by estrogen receptor (ER) status. To determine if being under care for heart disease biased the findings, rate ratios in users of angina drugs were similarly evaluated as a control exposure group. Women using digoxin and angina drugs were identified in the nationwide Danish Prescription Database, available between 1995 and 2008. Incident breast cancers were identified in the Danish Cancer Registry and further classifying by ER status. Relative risks (RR) were

EvidenceUpdates2011

12. Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation?

Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation? BestBets: Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation? Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation? Report By: Richard Parris - Locum Consultant Emergency Medicine Search checked (...) by Simon Clarke - Consultant Emergency Medicine Institution: Emergency Department Royal Bolton Hospital Date Submitted: 9th September 2004 Date Completed: 17th December 2009 Last Modified: 18th December 2009 Status: Green (complete) Three Part Question In a stable patient with [acute atrial fibrillation], is [treatment superior] with [calcium channel blockers or digoxin]? Clinical Scenario A 57 year old woman attends the Emergency Department with palpitations of uncertain duration. A diagnosis

BestBETS2010

13. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation

Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation 19487941 2009 06 18 2009 07 07 2013 11 21 1530-0293 37 7 2009 Jul Critical care medicine Crit. Care Med. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. 2174-9; quiz 2180 10.1097/CCM.0b013e3181a02f56 To compare (...) the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization. Randomized control trial. Acute emergency medical admission unit in a regional teaching hospital in Hong Kong. One hundred fifty adult patients with acute AF and rapid VR (>120 bpm). Patients were randomly assigned in 1:1:1 ratio to receive intravenous diltiazem, digoxin, or amiodarone for VR control

EvidenceUpdates2009

14. Are beta-blockers superior and safer to digoxin for rate control of acute atrial fibrillation in the emergency department?

Are beta-blockers superior and safer to digoxin for rate control of acute atrial fibrillation in the emergency department? BestBets: Are beta-blockers superior and safer to digoxin for rate control of acute atrial fibrillation in the emergency department? Are beta-blockers superior and safer to digoxin for rate control of acute atrial fibrillation in the emergency department? Report By: Martin Hossack - Medical Student Search checked by Rick Body - Specialist Registrar Institution: Manchester (...) Royal Infirmary Date Submitted: 7th July 2008 Date Completed: 9th January 2009 Last Modified: 14th November 2008 Status: Green (complete) Three Part Question In [patients presenting to the Emergency Department with atrial fibrillation requiring rate limitation] are [beta blockers superior in efficacy and safety to digoxin] in [achieving rate control]? Clinical Scenario A 60 year old man comes to the Emergency Department with symptoms of palpitations. ECG recording confirms atrial fibrillation

BestBETS2009

15. Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure

Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure 19064024 2008 12 09 2008 12 18 2016 10 19 1879-1913 102 12 2008 Dec 15 The American journal of cardiology Am. J. Cardiol. Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. 1681-6 10.1016/j.amjcard.2008.05.068 In the Digitalis Investigation Group trial, digoxin-associated decrease in the combined end point of heart failure (HF (...) ) hospitalization or HF mortality was significant in systolic but not in diastolic HF. To assess whether this apparent disparity could be explained by differences in baseline characteristics and sample size, we used propensity score matching to assemble a cohort of 916 pairs of patients with systolic and diastolic HF who were balanced in all measured baseline covariates. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) of the effect of digoxin on outcomes separately in systolic and diastolic

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

16. Digoxin increased risk of death in women, but not men, with heart failure

Digoxin increased risk of death in women, but not men, with heart failure Digoxin increased risk of death in women, but not men, with heart failure | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Digoxin increased risk of death in women, but not men, with heart failure Article Text Treatment Digoxin increased risk of death in women, but not men, with heart failure Free Elizabeth Rideout , RN, PhD Statistics from Altmetric.com No Altmetric data available for this article. ( 2002 ) N Engl J Med 347

Evidence-Based Nursing (Requires free registration)2004

17. Association of serum digoxin concentration and outcomes in patients with heart failure.

Association of serum digoxin concentration and outcomes in patients with heart failure. 12588271 2003 02 17 2003 02 27 2016 10 17 0098-7484 289 7 2003 Feb 19 JAMA JAMA Association of serum digoxin concentration and outcomes in patients with heart failure. 871-8 The Digitalis Investigation Group (DIG) trial reported that digoxin provided no overall mortality benefit and only a modest reduction in hospitalizations among patients with heart failure and depressed left ventricular systolic function (...) . The clinical outcomes associated with digoxin therapy at different serum concentrations in the DIG trial have not been assessed. To assess variations in serum digoxin concentration (SDC) and their association with mortality and hospitalization in patients with heart failure. Post hoc analysis of the randomized, double-blinded, placebo-controlled DIG trial, conducted from August 1991 to December 1995, with the main analysis restricted to men with a left ventricular ejection fraction of 45% or less (n = 3782

JAMA2003

18. Sex-based differences in the effect of digoxin for the treatment of heart failure.

Sex-based differences in the effect of digoxin for the treatment of heart failure. 12409542 2002 10 31 2002 11 08 2013 11 21 1533-4406 347 18 2002 Oct 31 The New England journal of medicine N. Engl. J. Med. Sex-based differences in the effect of digoxin for the treatment of heart failure. 1403-11 The Digitalis Investigation Group trial reported that treatment with digoxin did not decrease overall mortality among patients with heart failure and depressed left ventricular systolic function (...) , although it did reduce hospitalizations slightly. Even though the epidemiologic features, causes, and prognosis of heart failure vary between men and women, sex-based differences in the effect of digoxin were not evaluated. We conducted a post hoc subgroup analysis to assess whether there were sex-based differences in the effect of digoxin therapy among the 6800 patients in the Digitalis Investigation Group study. The presence of an interaction between sex and digoxin therapy with respect

NEJM2002

19. Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity

Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity DiDomenico R J, Walton S M, Sanoski C A, Bauman J L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study evaluated the use of digoxin immune Fab (FAB) in the treatment of patients with non-life-threatening digoxin toxicity. The use of FAB was compared to standard therapy. Standard therapy consisted of supportive care aimed at correcting electrolyte abnormalities, treating arrhythmias and correcting any precipitating

NHS Economic Evaluation Database.2000

20. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial.

Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. 10768435 2000 05 01 2000 05 01 2015 06 16 0140-6736 355 9208 2000 Mar 18 Lancet (London, England) Lancet Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. 967-72 Severe cardiac glycoside cardiotoxicity after ingestion of yellow oleander seeds is an important problem in rural areas of Sri Lanka. Currently, patients (...) must be transferred to the capital for temporary cardiac pacing. We did a randomised controlled trial to investigate whether anti-digoxin Fab could reverse serious oleander-induced arrhythmias. After a preliminary dose-finding study, 66 patients who presented to hospital with a serious cardiac arrhythmia were randomised to receive either 1200 mg of anti-digoxin Fab or a saline placebo. A 12-lead electrocardiogram, 3 min rhythm strip, and blood sample for measurement of electrolytes and cardiac

Lancet2000